Clinical trials: IBS, Diarrhea Predominant
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed…
- Trial name
- NCT00067457
- Testing
- alosetron
- Where
- 191 sites in United States, Australia
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01225237
- Testing
- Ramosetron
- Where
- 4 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Astellas Pharma Inc
Irritable Colon
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
- Trial name
- NCT00370032
- Testing
- alosetron
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to…
- Trial name
- NCT02419963
- Testing
- endoscopy for tissue biopsy, Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome With Diarrhea (IBS-D)
Curcumin, Vitamin D and Green Tea in IBS-D
Irritable Bowel Syndrome (IBS) is a highly prevalent condition of the gastrointestinal tract that has significant impact on sufferer's quality of life. The diarrhoea variant (IBS-D) makes up around one third of all IBS sufferers.
- Trial name
- NCT07052890
- Testing
- Curcumin, vitamin d and green tea extract
- Where
- 3 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Dr Anthony Hobson
Irritable Bowel Syndrome With Diarrhoea
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea.
- Trial name
- MIBS (NCT01316718)
- Testing
- Mesalazine
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- University of Nottingham
Irritable Bowel Syndrome
Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS
Acupuncture has been used for centuries in China in the treatment of diarrhea. Our hypothesis is that acupuncture is effective in the treatment of abdominal pain and diarrhea in patients with diarrhea-predominant IBS
- Trial name
- NCT00219505
- Testing
- acupuncture
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Penn State University
IBS, Diarrhea Predominant
Transcutaneous Electrical Acustimulation for IBS-D: A Multicenter Study
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits.
- Trial name
- NCT07425145
- Testing
- Portable stimulator
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Foshan
Irritable Bowel Syndrome
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome…
- Trial name
- NCT02328547
- Testing
- Fecal microbiota transplantation capsules
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Montefiore Medical Center
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile…
- Conditions
- Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI), Fecal Microbiota Therapy (FMT), Irritable Bowel Syndrome (IBS)
- Trial name
- ORAL-LYO-FMT (NCT06948461)
- Testing
- ORAL-LYO-FMT
- Volunteers
- 63 people
- Sponsor
- PharmaPlanter Technologies Inc
Irritable Bowel Syndrome
Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is the most common functional GI disorder in which abdominal pain and/or discomfort is associated with changes in bowel habit, and with features of disordered defecation.
- Trial name
- NCT02545413
- Testing
- Probiotic VSL#3
- Where
- India
- Sponsor
- Next Gen Pharma India Pvt. Ltd.
IBS, Diarrhea Predominant
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial. Its purpose is to evaluate the efficacy and safety of Changji'an Capsules in subjects with diarrhea-predominant…
- Trial name
- NCT07610434
- Testing
- Chang Ji'an capsule, Chang Ji'an capsule mimic
- Where
- 29 sites in China
- Volunteers
- 636 people
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will…
- Trial name
- NCT03729271
- Testing
- Rifaximin, Glucose and lactulose hydrogen breath testing
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- University of Michigan
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Irritable Bowel Syndrome
Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients
Probiotics may improve symptoms in IBS patients. The aim of this study is to test the efficacy of Lactobacillus FARCIMINIS in diarrhea predominant IBS patients according to Rome III criteria.
- Trial name
- NCT00561535
- Testing
- Lactobacillus FARCIMINIS
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
IBS (Irritable Bowel Syndrome)
Transcranial Magnetic Stimulation and Pharmacologic/Probiotic Interventions for Diarrhea-Predominant IBS
What is the study about? This study is for adults with diarrhea-predominant irritable bowel syndrome (IBS-D) who suffer from chronic visceral pain.
- Trial name
- rTMS (NCT07172139)
- Testing
- Active rTMS + Pinaverium Bromide, Active rTMS + Bifidobacterium
- Volunteers
- 140 people
- Sponsor
- Rui Li
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc